Advertisement

Tumor Biology

, Volume 37, Issue 10, pp 13445–13453 | Cite as

Downregulation of SLC5A8 inhibits hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling

  • Ben-Shun Hu
  • Shu-Ming Xiong
  • Gang Li
  • Jian-Ping Li
Original Article

Abstract

SLC5A8 has been shown to be associated with a large number of cancer progressions. However, the biological functions of SLC5A8 in hepatocellular carcinoma (HCC) remain largely unclear. Therefore, we performed this research to explore the functions of SLC5A8 in HCC progression. In this study, SLC5A8 protein and mRNA expression were examined by immunohistochemistry and quantitative real-time PCR, respectively, and we found significantly lower expression levels in HCCs than in the corresponding normal liver tissues. Low SLC5A8 expression was significantly correlated with the clinicopathological features of HCC patients. Patients with low SLC5A8 expression have a shorter overall survival time. This interpretation is confirmed by the results obtained from our in vitro experiments; functional assays indicated that overexpression of SLC5A8, by infection with a recombinant plasmid containing SLC5A8, significantly suppressed HCC cell growth, invasion, and migration and induced HCC cell apoptosis. Moreover, the expression levels of beta-catenin, cyclin D1, c-Myc, MMP-2, and FAK detected by western blotting were downregulated in SLC5A8-transfected HCC cells compared with control-transfected cells, indicating that SLC5A8 has a tumor-suppressive function that acts by interfering with Wnt/β-catenin signaling in HCC.

Keywords

SLC5A8 Hepatic cancer Biomarker Prognosis Wnt/β-catenin signaling 

Notes

Acknowledgments

This project was supported by the Jiangsu Provincial Natural Science Foundation of China (Grant No. BK20131095).

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis. 2009;27:80–92. doi: 10.1159/000218339. PubMedGoogle Scholar
  2. 2.
    Fernandez-Banet J, Lee NP, Chan KT, Gao H, Liu X, Sung W-K, et al. Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma. Genomics. 2014;103:189–203. doi: 10.1016/j.ygeno.2014.01.003. CrossRefPubMedGoogle Scholar
  3. 3.
    Wu JN, Roberts CW. ARID1A mutations in cancer: another epigenetic tumor suppressor? Cancer Discov. 2013;3:35–43. doi: 10.1158/2159-8290.CD-12-0361.CrossRefPubMedGoogle Scholar
  4. 4.
    Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–63. doi: 10.1002/hep.22580. CrossRefPubMedGoogle Scholar
  5. 5.
    Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674–87. doi: 10.1038/nrc1934. CrossRefPubMedGoogle Scholar
  6. 6.
    Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312–27. doi: 10.1002/hep.22506. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gopal E, Miyauchi S, Martin PM, Ananth S, Roon P, Smith SB, et al. Transport of nicotinate and structurally related compounds by human SMCT1 (SLC5A8) and its relevance to drug transport in the mammalian intestinal tract. Pharm Res. 2007;24:575–84. doi: 10.1007/s11095-006-9176-1.CrossRefPubMedGoogle Scholar
  8. 8.
    Martin PM, Gopal E, Ananth S, Zhuang L, Itagaki S, Prasad BM, et al. Identity of SMCT1 (SLC5A8) as a neuron-specific Na+-coupled transporter for active uptake of L-lactate and ketone bodies in the brain. J Neurochem. 2006;98:279–88. doi: 10.1111/j.1471-4159.2006.03878.x. CrossRefPubMedGoogle Scholar
  9. 9.
    Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life Sci. 2006;78:2419–25. doi: 10.1016/j.lfs.2005.10.028. CrossRefPubMedGoogle Scholar
  10. 10.
    Thangaraju M, Gopal E, Martin PM, Ananth S, Smith SB, Prasad PD, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. Cancer Res. 2006;66:11560–4. doi: 10.1158/0008-5472.CAN-06-1950. CrossRefPubMedGoogle Scholar
  11. 11.
    Park JY, Kim D, Yang M, Park HY, Lee SH, Rincon M, et al. Gene silencing of SLC5A8 identified by genome-wide methylation profiling in lung cancer. Lung Cancer. 2013;79:198–204. doi: 10.1016/j.lungcan.2012.11.019.CrossRefPubMedGoogle Scholar
  12. 12.
    Dong SM, Lee EJ, Jeon ES, et al. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol. 2005;18:170–8. doi: 10.1038/modpathol.3800261. CrossRefPubMedGoogle Scholar
  13. 13.
    Ganapathy V, Gopal E, Miyauchi S, Prasad PD. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans. 2005;33:237–40. doi: 10.1042/BST0330237. CrossRefPubMedGoogle Scholar
  14. 14.
    Hong C, Maunakea A, Jun P, Bollen AW, Hodgson JG, Goldenberg DD, et al. Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Cancer Res. 2005;65:3617–23. doi: 10.1158/0008-5472.CAN-05-0048. CrossRefPubMedGoogle Scholar
  15. 15.
    Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 2005;90:3028–35. doi: 10.1210/jc.2004-1394. CrossRefPubMedGoogle Scholar
  16. 16.
    Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, et al. Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol. 2004;25:134–40. doi: 10.1159/000079145. CrossRefPubMedGoogle Scholar
  17. 17.
    Park JY, Zheng W, Kim D, Cheng JQ, Kumar N, Ahmad N, et al. Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev. 2007;31:359–65. doi: 10.1016/j.cdp.2007.09.002. CrossRefPubMedGoogle Scholar
  18. 18.
    Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA, et al. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008;36:e32–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A. 2003;100:8412–7. doi: 10.1073/pnas.1430846100. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Paroder V, Spencer SR, Paroder M, Arango D, Schwartz S, Mariadason JM, et al. Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. Proc Natl Acad Sci U S A. 2006;103:7270–5. doi: 10.1073/pnas.0602365103. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood. 2008;112:2013–6. doi: 10.1182/blood-2008-01-128595.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 23.
    Liu WB, Liu JY, Ao L, Zhou ZY, Zhou YH, Cui ZH, et al. Epigenetic silencing of cell cycle regulatory genes during 3-methylcholanthrene and diethylnitrosamine-induced multistep rat lung cancer. Mol Carcinog. 2010;49:556–65. doi: 10.1002/mc.20621. CrossRefPubMedGoogle Scholar
  23. 24.
    Xu J, HY X, Zhang Q, Song F, Jiang JL, Yang XM, et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res. 2007;5:605–14. doi: 10.1158/1541-7786.MCR-06-0286. CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Hepatobiliary Pancreatic CenterThe Third Hospital Affiliated to Nantong UniversityWuxiChina
  2. 2.Department of Hepatobiliary Pancreatic Center, Changhai HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations